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Osteoporosis is becoming a major health burden that mainly
occurs in the aging population, especially in post-
menopausal women [1]. Osteoporosis is characterized by
the imbalance in bone formation and resorption. Excessive
bone resorption leads to low bone mineral density (BMD)
and the deterioration of bone microarchitecture, which
results in a loss of bone strength and an increase in fracture
risks [2]. According to the World Health Organization,
osteoporosis is defined as BMD with > 2.5 standardore) Pte Ltd. This is an open access article under the CC BY-NC-ND
2 P.K. Suen, L. Qindeviations below the young adult average BMD, calculated
as a T-score of 2.5 [3,4]. Lifetime risk of osteoporotic
fracture at age 50 years is estimated to range from 13e22%
in men and 40e53% in women in western countries [2]. In
Hong Kong, the incident rates (per 100,000 population) of
hip fracture at age >65 years are 342 and 703 for men and
women, respectively [5], while the prevalence of radio-
graphic vertebral fracture (mean age 72 years) are 15% and
17% for men and women, respectively [6]. The prevalence
of osteoporosis and osteoporotic fracture has generated
huge social and economic impact.
Drug therapy is an effective way to prevent osteopo-
rosis. Bisphosphonates are a class of antiresorptive drugs
that inhibit bone resorption and have been widely used to
treat osteoporosis. Bisphosphonates have a high binding
affinity to bone minerals and induce osteoclasts apoptosis
during bone resorption [7]. Denosumab is another anti-
resorptive drug, a humanized monoclonal antibody that
inhibits the binding of receptor activator of nuclear factor
kB ligand (RANKL) to its receptor, leading to inhibition of
osteoclast development, formation and survival [8].
Although antiresorptive drugs are effective against oste-
oporosis, their adverse effects include atypical long bone
fractures after long-term treatment and an increase in
the risk of jaw osteonecrosis at higher doses [9e11]. In
fracture healing, bisphosphonate treatment does not
impair fracture union in healthy rats [12,13], but the
callus remodelling is delayed in ovariectomised (OVX) rats
[14], suggesting that the role of bisphosphonates in
improving fracture healing remains controversial [15,16].
Furthermore, antiresorptive drugs, such as bisphospho-
nates and denosumab, are unable to rebuild bone that has
been lost, so there is a need for an anabolic drug to
promote bone building. Teriparatide [recombinant human
parathyroid hormone (1e34), rhPTH1-34] was the first
Food and Drug Administration (FDA) approved anabolic
drug against osteoporosis [17]. Teriparatide exerts its
anabolic activity through increased osteoblasts number
and activity, increasing the osteogenic differentiation of
mesenchymal stem cells (MSCs), and decreasing osteo-
blasts apoptosis [18e20]. However, teriparatide delivery
is inconvenient as it requires daily subcutaneous in-
jections, when compared with bisphosphonates, which
are taken orally. In addition, due to the potential risk of
osteosarcoma, the use of teriparatide is limited to a
maximum treatment of 2 years [21,22]. In light of these
achievements, developing new drugs for treating osteo-
porosis continues to be a necessity.
The recent discoveries and advances in the molecular
pathophysiology of osteoporosis have led to the develop-
ment of new therapeutic drugs for osteoporosis treatment,
such as the sclerostin monoclonal antibody as a new
anabolic drug for osteoporosis [23,24]. Sclerostin, an in-
hibitor of the Wnt/b-catenin signalling pathway that regu-
lates bone growth, has become an attractive therapeutic
target for treating osteoporosis. In this review, recent
findings of sclerostin, and its potential as an effective drug
target for treating osteoporosis and osteoporotic fractures,
are summarized, together with the findings of preclinical
experiments.Cellular events of bone remodelling and
osteoporosis
Our skeleton is constantly undergoing bone remodelling in
response to mechanical loading, microdamage repair, and
mineral homeostasis. The activation of the bone remod-
elling process is mediated by osteocytes through osteocyte
apoptosis, which recruits osteoclasts precursor cells for
bone resorption [25]. The osteoclasts precursor cells,
originated from the hematopoietic lineage, then differ-
entiate into osteoclasts to resorb the bone matrix [26,27].
Besides osteocytes, osteoblasts also regulate bone
resorption though the expression of the RANKL and
osteoprotegerin [28,29]. The resorption of bone matrix by
osteoclasts results in the release of growth factors to re-
cruit osteoblasts for bone formation [30]. Therefore, the
bone remodelling process is tightly regulated by the
balanced activity of bone formation by osteoblasts and
bone resorption by osteoclasts, through extensive cross-
talk between the osteocytes, osteoblasts, and osteoclasts.
Osteoporosis is caused by the imbalance of the bone for-
mation and bone resorption, with the rate of bone
resorption exceeding the rate of bone formation [31].
Peak bone mass is achieved at around age 30 years, and,
after that, bone is lost with increasing age [32,33]. Bone
loss is accelerated in postmenopausal women due to the
absence of oestrogen, which stimulates osteoblast
apoptosis and osteoclast activity, resulting in osteoporosis
[34].
Sclerostin and skeletal mass
Sclerosteosis is a rare autosomal recessive gene disorder
characterized by its high bone mass phenotype in radio-
graphs and an increased BMD in lumbar spine, hip and
forearm [35e37]. Patients affected by sclerosteosis carry
a loss of functional mutation of the sclerostin gene, which
is caused by either nonsense mutations near the 50 region
of the sclerostin mRNA transcript or mutations that affect
the correct splicing and stability of the transcript [35,36].
In a similar high bone mass disorder, van Buchem disease,
the sclerostin gene is not mutated, but the 52-kb region
downstream of the sclersotin gene is deleted [38]. This 52-
kb region contains an enhancer element (termed ECR5) for
proper sclerostin gene expression, thus result in the loss of
sclersotin gene expression in the van Buchem disease [39].
Sclerostin is a secreted glycoprotein that is mainly
expressed in bone matrix and cartilage matrix and has
been reported to suppress the mineralization of osteo-
blasts in cell culture environment [36,40]. The function of
sclerostin as an inhibitor of bone formation has been
further demonstrated in transgenic mice. Sclerostin knock
out (SOST-KO) mice displays a high bone mass with
increased bone formation and bone strength [41,42],
whereas overexpression of sclerostin in mice results in low
bone mass with decreased bone formation and bone
strength [40,43]. Sclerostin inhibits bone formation
through inhibiting the Wnt/b-catenin signalling [44], and
its expression is regulated by mechanical unloading and
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catenin signalling is important for osteoblast differentia-
tion and proliferation [49]. Sclerostin has been found to be
responsible for both inhibition of the osteoblastogenesis
and preosteocyte differentiation of osteoblasts [50,51].
Sclerostin also stimulates RANKL secretion from osteo-
cytes to induce osteoclastogensis [52,53], leading to an
increase in bone resorption. In addition, osteoclasts
induce osteoblasts for bone formation through the Wnt
signalling pathway [54,55]. Inhibitors of the Wnt signalling
pathway (such as Dickkopf-related protein 1, DKK1) sup-
press the osteoclasts-mediated osteoblast bone formation
[54]. This suggests that sclerostin may also suppress the
osteoclast-mediated osteoblast bone formation. It is also
demonstrated that sclerostin is expressed in osteoclasts
from aged mice, indicating that sclerostin contributes to
the age-related decoupling of bone turnover [56]. Taken
together, these data show that sclerostin plays an impor-
tant role in modulating bone formation and bone turnover,
through antagonizing the Wnt/b-catenin signalling
pathway in osteoblasts and modulating RANKL level that
act on osteoclasts (Figure 1).Figure 1 The molecular mechanisms of sclerostin in modulating b
bone turnover via responding to mechanical unloading or oestrogen
osteogeneic differentiation of mesenchymal stem cells or osteoprog
stimulates RANKL secretion from osteocytes, where RANKL is essent
that sclerostin is also expressed in osteoclasts in aged mice [56].Molecular biology of sclerostin and Wnt/b-
catenin signalling pathway
Sclerostin is an antagonist of the Wnt/b-catenin
signalling pathway
Sclerostin is a secreted glycoprotein that is mainly
expressed by osteocytes [57]. The serum level of sclerostin
increases with age, in both men and women [58]. Although
serum sclerostin is positively correlated with BMD in post-
menopausal women, it is negatively correlated with bone
turnover markers. This suggests that the serum sclerostin
level is generally reflected by the number of osteocytes
where osteocytes number is higher in high BMD individuals
[59]. In fact, sclerostin may act as a paracrine rather than
endocrine signalling molecule for osteoblasts functions, as
its target cells, the osteoblasts, are in close proximity with
osteocytes.
The Wnt/b-catenin signalling pathway plays an impor-
tant role in regulating cell proliferation and differentiation,
including osteoblasts and its differentiation from MSCs
[55,60]. The Wnt proteins are secreted glycoproteins thatone turnover. Sclerostin is secreted by osteocytes to modulate
deficiency. Sclerostin inhibits bone formation by inhibiting the
enitor cells and the proliferation of osteoblasts. Sclerostin also
ial for osteoclasts formation and activity. A recent study shows
4 P.K. Suen, L. Qinstimulate the signalling pathway through binding to the
receptors low-density lipoprotein receptor-related protein
5/6 (LRP5/6) and co-receptor Frizzled. The receptor com-
plex prevents the phosphorylation of b-catenin by inhibiting
the glycogen synthase kinase 3 (GSK3) activity involving the
protein complex with Disheveled (Dsh), Axin and adeno-
matous polyposis coli (APC) [61]. This results in cytoplasmic
accumulation and subsequent nuclear translocation of b-
catenin [60]. Beta-catenin is a transcriptional coactivator
that interacts with other transcription factors to mediate
downstream gene expression, leading to cell differentiation
and proliferation [55] (Figure 2).
Wnt signalling is also tightly regulated by several types
of secreted antagonists, such as sclerostin and DKK1 [62].Figure 2 Sclerostin and the Wnt/b-catenin signalling pathway.
pathway. Sclerostin binds to LRP5/6 receptors, replaces the Wnt p
GSK3/Axin/APC protein complex is released to the cytosol and phos
degraded by proteasome. In addition, the sclerostin-LRP5/6 interac
degradation. (B) The Wnt/b-catenin signaling is activated through t
receptor Frizzled. The receptor complex prevents the phosphorylat
cytosolic accumulation of b-catenin. The b-catenin then transloca
Injection of Scl-Ab eliminates the inhibitory effects of sclerostin an
polyposis coli; DshZ Dishevelled; GSK3Z glycogen synthase kinase
5/6; Scl-Ab Z sclerostin monoclonal antibody; SOST Z sclerostin.Similar to the role of sclerostin in bone formation in mice,
DKK1 also negatively regulates bone formation. Bone-
specific DKK1 overexpression in transgenic mice resulted
in osteopenia [63]. Deleting both DKK1 alleles was lethal,
while deleting a single allele of DKK1 gene increased bone
mass [64]. It is further demonstrated that DKK1 expression
level is inversely proportional to the bone mass in mice
[65]. Sclerostin and DKK1 inhibit the Wnt signalling pathway
through binding to LRP5/6, displacing the Wnt proteins,
leading to the dissociation of the LRP5/6 and Frizzled re-
ceptor complex [66e68]. This results in phosphorylation of
b-catenin and eventually degraded by proteasome
(Figure 2). In addition, DKK1 was also found to mediate the
recruitment of Kremen co-receptor to LRP5/6 and induced(A) Sclerostin is an antagonist of the Wnt/b-catenin signalling
roteins and disrupts the Wnt-LRP5/6-Frizzled interaction. The
phorylates the b-catenin. The phosphorylated b-catenin is then
tion leads to internalization into the endosome and subsequent
he interaction of Wnt proteins with the receptor LRP5/6 and co-
ion of b-catenin by GSK3/Dsh/Axin/APC complex that results in
tes to the nucleus and activates transcription of target genes.
d activates the Wnt/b-catenin signaling. APC Z adenomatosis
-3; LRP5/6Z low-density lipoprotein receptor-related protein
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mediated signalling [66,67]. Recently, sclerostin has been
found to mediate the endocytosis of LRP6 upon its binding
to LRP6 [68]. The clathrin-dependent endocytosis of
sclerostin-LRP6 complex is degraded in a proteasome-
dependent manner [68], possibly within the endosome [69].
Mutations in the N-terminal human LRP5 protein that
reduce its affinity to sclerostin and result in a high bone
mass disorder further demonstrate the importance of
sclerostin-LRP5 interaction in regulating bone mass [70,71].
Meanwhile, b-catenin activity is required for osteoblast
differentiation of MSCs. Activation of Wnt signalling
pathway in mouse MSCs culture upregulated Runx2
expression [49], while inactivation of b-catenin in MSCs in
transgenic mice resulted in the loss of factors required for
osteoblast differentiation, such as Runx2 and Osx, and
disrupted osteoblast differentiation [72]. It has also been
discovered that b-catenin activity in MSCs promotes
osteoblastogenesis and inhibits chondrogenesis [72].Molecular structure of sclerostin and its
interaction with LRP5/6
Structural analysis of sclerostin and LRP5/6 provides more
detailed information on how they interact. Sclerostin con-
tains a cystine-knot motif with a flexible loop domain
flanked by two fixed-structure finger domains [73]. Later, it
is demonstrated that the PNAIG motif presence in the
flexible loop domain of sclerostin is responsible for its
interaction with the LRP6 receptor [74]. It was also shown
that effective sclerostin monoclonal antibody binds to this
region to interfere with the sclerostin-LRP interaction [75].
The LRP5/6 is a transmembrane protein. The extracellular
domain of LRP5/6 consists of four b-propeller domains
separated by four EGF domains, followed by LDLA repeats,
transmembrane domains and a cytoplasmic domain [76].
The cytoplasmic domain is involved in recruiting the GSK3/
Dsh/Axin/APC complex, whereas the extracellular domain
is responsible for Wnt ligand binding and subjected to
antagonist inhibition. Structural analysis reveals that the
first two propeller domain (E1E2) of LRP6 are necessary for
both sclerostin and Wnt ligand binding, suggesting that
sclerostin and Wnt1 compete for the same binding site of
LRP6 [76]. Conformational changes in the LRP6 propeller
domains and/or steric hindrance effects of sclerostin may
also be responsible for sclerostin inhibition of other Wnt
ligands binding to LRP6 [76].Regulation of sclerostin expression
Given that sclerostin is important for regulating bone for-
mation, it is not surprising that the expression of sclerostin
is tightly regulated by various factors, including mechanical
stimuli, oestrogen deficiency, vitamin D, Prostaglandin E2,
parathyroid hormone (PTH), and transforming growth fac-
tor (TGF)-b. The expression of sclerostin is upregulated in
tibia in a hindlimb unloading model (tail suspension) in
mice and downregulated in ulna in loading model in both
rat and mice [45]. It is further demonstrated that sclerostin
downregulation in osteocytes is required for osteogenesisin mechanical loading condition in transgenic mice [46],
and SOST-KO mice are resistant to bone loss due to me-
chanical unloading [42]. Oestrogen deficiency also stimu-
lates sclerostin expression. Sclerostin expression is
upregulated in the femora of OVX mice, which is reversed
by b-oestradiol injection [47]. In postmenopausal women,
oestrogen treatment significantly reduces the sclerostin
level in bone and serum [48]. These data indicate that
sclerostin plays an important role in bone loss during oes-
trogen deficiency in postmenopausal osteoporosis and me-
chanical unloading conditions in immobilization after
osteoporotic fracture.
Vitamin D (1,25-dihydroxyvitamin D3) is an important
regulator of calcium homeostatsis. Vitamin D treatments
increases serum sclerostin level in healthy [77] or vitamin D
deficient/insufficient [78] aged adults, but decreased
serum sclerostin level in young women with vitamin D
deficiency [79]. The relationship between vitamin D treat-
ment and sclerostin expression has been examined in more
detail in a recent study using human osteoblast cell cul-
tures. It was shown that vitamin D stimulates sclerostin
gene expression through the vitamin D response element
presence in the upstream promoter region of human scle-
rostin gene [80]. In addition, in SOST-KO mice, the serum
vitamin D and phosphorus is increased and renal excretion
of calcium is decreased, indicating a positive mineral bal-
ance in the deletion of sclerostin [81]. Taken together,
these reports suggest that the vitamin D and sclerostin
control of calcium homeostasis and bone growth is complex
[82].
Prostaglandin E2 is a lipid-derived hormone that is found
to be involved in activation of b-catenin signalling in
response to mechanical loading [83,84]. Mechanical loading
induces the synthesis and release of prostaglandin E2, upon
binding to its receptor, and suppression of sclerostin
expression [85,86]. In a b-catenin reporter transgenic
mouse model, it shows rapid response of osteocytes to
mechanical loading [84]. As early as 1 hour after in vivo
loading of ulna, b-catenin expression is upregulated, and
pretreatment of inhibitor of prostaglandin E2 synthesis di-
minishes the b-catenin expression during mechanical
loading [84]. In cell culture models, inhibition of prosta-
glandin E2 synthesis prevents the sclerostin downregulation
in response to mechanical stimulation [85,86].
TGF-b is an important regulator of stem cell differenti-
ation and proliferation. During osteogenic differentiation,
TGF-b regulates b-catenin signalling, and can either pro-
mote or inhibit osteogenic differentiation depending on
environmental clues [87]. TGF-b enhanced sclerostin
expression in mature osteoblasts and regulated sclerostin
expression through the ECR5 enhancer element on the
downstream enhancer region of sclerostin [88].
The expression of sclerostin is regulated at transcrip-
tional level by PTH. Decreased sclerostin expression is
observed in PTH-treated mice and transgenic mice over-
expressing PTH receptor in osteocytes [89,90]. Similar re-
sults are observed in clinical studies, where the serum
sclerostin level is negatively correlated with PTH level,
especially for postmenopausal women [91,92], and PTH
administration reduces the serum sclerostin level [93,94].
These results indicate that the anabolic effects of PTH act
through inhibiting the sclerostin expression.
6 P.K. Suen, L. QinThe 52-kb downstream enhancer region of sclerostin
gene plays an important role in regulating sclerostin gene
expression. This 52-kb region contains an ECR5 enhancer
element, and the transcriptional activity of ECR5 is
controlled by the myocyte enhancer factor-2c (MEF2C)
transcription factor [95]. Mice lacking ECR5 or bone-specific
expression of MEF2C display a high bone mass phenotype
with low sclerostin expression, indicating the importance of
MEF2C and its binding to ECR5 enhancer for controlling
sclerostin transcription [95,96]. Several factors are
responsible for regulating the binding of MEF2C to its
responsive sequence, including PTH and TGF-b [88,97].
Histone deacetylases (HDACs) are a class of histone-
modifying enzymes that remove the acetyl group from
histone proteins and result in stronger histoneeDNA inter-
action and suppress gene expression. In bone, HDAC5 is a
negative regulator of sclerostin expression through blocking
the binding of MEF2C to the sclerostin enhancer region [98].
Overexpression of HDAC5 in osteocyte cell cultures sup-
presses sclerostin expression [99], while knockout of HDAC5
in osteocyte cell cultures or transgenic mice results in
increased sclerostin expression [98].
Taken together, these data show that the regulation of
sclerostin expression is complex and controlled by various
factors. Mechanical signals and hormonal signals are major
players in regulating sclerostin expression in osteocytes.
The binding of MEF2C to its binding sites on the 52-kb
downstream enhancer region of sclerostin gene are sub-
jected to the control of various factors, including PTH,
TGF-b, and HDAC5, which in turn, is crucial for sclerostin
expression. In addition, the roles of MEF2C (and HDAC5) in
regulating sclerostin expression in other signalling path-
ways, such as mechanical signals or oestrogen deficiency
remain largely unknown and require future research.
However, it is possible that MEF2C is the major player in
regulating sclerostin expression, as the 52-kb enhancer
region controls sclerostin expression.Other drug treatments for osteoporosis
treatment
Besides bisphosphonates, Odanacatib and denosumab are
two antiresorptive drugs that are recently under clinical
trials or have been approved by the FDA to treat post-
menopausal osteoporosis. Denosumab was approved by FDA
in 2010 [100], and Odanacatib has just finished Phase 3
clinical trials [101].
Denosumab is a fully humanized anti-RANKL antibody
that suppresses the development and activity of osteoclasts
and results in decreasing bone resorption and increasing
BMD [102]. In a Phase 2 clinical study on postmenopausal
women, it was reported that denosumab treatment signif-
icantly increased the BMD at lumbar spine, total hip, and
radius [103]. Denosumab treatment has also been found to
be able to reduce the level of serum bone resorption
marker and increase the level of serum bone formation
marker [103]. Although the reduced BMD at lumbar spine
and hip back to baseline level is observed in discontinued
denosumab treatment, the BMD increased again when the
treatment restarts [103]. In a large-scale Phase 3 clinical
study, it was reported that denosumab treatmentsignificantly reduced the fracture risk of postmenopausal
women [104].
Odanacatib is a small molecule inhibitor of cathepsin K
activities. Cathepsin K is a lysosomal protease that mainly
expresses in osteoclasts to degrade collagen I during bone
resorption [105]. Odanacatib treatment reduces bone
resorption activity of osteoclasts, but has no effect on
osteoclast formation and survival, suggesting that these
osteoclasts are able to stimulate or maintain osteoblast
activity for bone formation [105]. In fact, elevated bone
formation rate has been observed in cathepsin K- deficient
mice and Odanacatib-treated rabbits [106,107], indicating
both antiresorptive and anabolic effects of Odanacatib
treatment. In a Phase 2 clinical trial on postmenopausal
osteoporotic women with low bone mass, Odanacatib
treatment significantly increased the BMD at the spine and
hip in a dose-dependent manner [108]. The serum bone
resorption markers significantly decreased in the Odana-
catib treatment while the bone formation markers tran-
siently decreased initially, and returned to the baseline
level at the end of the 2-year study [108]. In the extended
3-year study, a progressive increase in BMD in spine,
femoral neck, and hip were observed in continuous Oda-
nacatib treatment [109], while discontinued Odanacatib
treatment resulted in a gradual decline of BMD to the
baseline level [109]. The bone resorption markers
continued to decline with continuous Odanacatib treat-
ment, while the bone formation markers remained at
baseline level [109]. A large-scale Phase 3 clinical trial has
been designed to assess the fracture prevention efficacy
and safety of Odanacatib in postmenopausal women with
osteoporosis [101].
Sclerostin monoclonal antibody for treatment
of osteoporosis
Scl-Ab treatment in animal models
Inhibiting antagonists of the Wnt signalling pathway pro-
vides an attractive strategy for treatment of osteoporosis.
Sclerostin monoclonal antibody (Scl-Ab) inhibits the func-
tion of sclerostin, thus re-activating the Wnt signalling
pathway in osteoblasts has provided an excellent thera-
peutic approach to enhance bone formation (Figure 2). As
sclerostin is mainly expressed in osteocytes [40,57], it is
expected that Scl-Ab treatment is bone specific with minor
side effects.
In normal rodents and nonhuman primates, Scl-Ab
treatment has been reported to increase bone formation,
bone mass and bone strength in a dose-dependent manner
[110,111]. In a study of animal model of osteoporosis, OVX
rats, Scl-Ab treatment also significantly increased bone
formation, bone mass, and bone strength of the animals
[112]. The increase in bone formation is illustrated by the
increase in osteoblasts number and serum bone formation
markers, and a decrease in bone resorption as illustrated by
decrease in osteoclast number [110e112]. Similar bone
anabolic effects of Scl-Ab treatment have also been
observed in male animal models. Scl-Ab treatments in 6-
month-old male rats, aged (16-month-old) male rats, and
male cynomolgus monkeys have displayed improvement of
Sclerostin in osteoporosis and treatment 7bone formation, bone mass, and bone strength at spine and
femur [113,114]. The effects of Scl-Ab on vertebral body
with different bone marrow composition are studied in
more details in aged female rats. Scl-Ab treatment is able
to increase bone volume fraction and trabecular thickness
in both yellow (fat) marrow rich fifth caudal vertebral body
and red marrow rich fourth lumbar vertebral body, indi-
cating that Scl-Ab is effective in increasing bone formation
regardless of bone marrow composition [115]. An increase
in the mineralization surface, mineral apposition rate and
bone formation rate, as well as decrease in the eroded
surface, have also been observed in both caudal and lumbar
vertebral bodies in a dose dependent manner [115]. Taken
together, Scl-Ab treatment increases the serum bone for-
mation markers and decreases the bone resorption
markers, which indicates that bone formation and bone
resorption are uncoupled in Scl-Ab treatment, thus creating
a large therapeutic window for osteoporosis treatment
[116].
Besides OVX-induced osteoporosis, the effects of Scl-Ab
treatment in other animal models have also been reported.
In an animal study of hindlimb unloading, Scl-Ab treatment
increases the bone formation, bone mass, and bone
strength through increasing bone formation and inhibiting
bone resorption [111,117]. Scl-Ab treatment is also shown
to have enhanced fracture healing and bone repair, with
increased bone formation, accelerated fracture repair and
fracture callus strength in rat studies [118e120] as well as
bilateral fibular osteotomy in cynomolgus monkeys [114].Clinical trials of Scl-Ab for osteoporosis
treatment
Supported by the encouraging results in the animal studies,
clinical trials were conducted to investigate the effects and
efficacy in humans, including those with normal bone mass
or low bone mass.
A Phase 1 clinical trial of Scl-Ab has been conducted on
postmenopausal women and healthy men with normal bone
mass. Scl-Ab is proven to improve significantly the BMD in
lumbar spine and hip, which is possibly due to the increased
bone formation and decreased bone resorption as in the
serum markers [121]. In the next study on postmenopausal
women and healthy men with low bone mass (BMD T-score
between 2.5 and 1.0), Scl-Ab treatment improved the
BMD in a dose-dependent manner with minor adverse ef-
fects [23]. Minor adverse effects include headaches, upper
respiratory tract infections, arthralgia, back pain, abdom-
inal pain, and pain in the hands and feet; the percentages
of participants reporting adverse events are similar in the
placebo group and pooled Scl-Ab treatment groups [23].
Scl-Ab treatment-specific adverse effectsdinjection site
reaction and paindare also reported [23]. Scl-Ab treatment
increases the serum bone formation markers and decreases
bone resorption markers as early as 1 week after the first
injection [23]. Scl-Ab also significantly increases the BMD at
lumbar spine and hip as early as 3 months after the first
injection [23].
In a Phase 2 clinical trial study, the efficacy of various
doses of Scl-Ab is compared with placebo or other osteo-
porotic drug treatments (alendronate and teriparatide) inpostmenopausal women with low BMD (T-score < 2.0 at
the lumbar spine) over a 12-month treatment period [24].
Similar to the Phase 1 clinical study, Scl-Ab was found to
have efficiently improved the BMD at the lumbar spine, hip,
and femoral neck as early as 3 months after the first in-
jection compared with placebo controls in a dose-
dependent manner with minor adverse effects [24]. The
adverse effects are similar to those reported in the Phase 1
clinical trial [24]. Additional adverse effects are gastroen-
teritis, constipation, bronchitis, urinary tract infection,
musculoskeletal pain, and fatigue [24]. The percentages of
adverse effects are similar in both pooled placebo group
and Scl-Ab treatment group [24]. The increased bone for-
mation markers and decreased bone resorption markers are
observed as early as 1 week after the first injection [24].
Compared with alendronate and teriparatide, a 210 mg
monthly dose of Scl-Ab treatment provides the best
improvement in BMD, starting as early as 6 months after the
first injection [24]. Currently, Scl-Ab is in Phase 3 clinical
trials to evaluate its effects in postmenopausal women with
low BMD (T-score < 2.5).
Given the large improvement of BMD in clinical trials of
Scl-Ab treatment in osteoporosis, we can expect the frac-
ture risk to be lowered with Scl-Ab treatment, provided
that Scl-Ab treatment improves the bone strength in the
preclinical studies. It is thus worth tracing the fracture
rates of the patients after Scl-Ab treatment in future
studies.
Future perspectives of Scl-Ab in osteoporosis
treatment
Long-term safety of Scl-Ab treatment
The effects of long-term Scl-Ab treatment are still under
investigation. Currently, there are two studies focusing on
the bone formation and bone strength of long-term effects
(26 weeks) of Scl-Ab on OVX rats. Long-term Scl-Ab treat-
ment progressively increases the bone mass and bone
strength in OVX rats, which is explained by an increase in
cortical and trabecular bone formation and reduced oste-
oclast activity [122]. In addition, Scl-Ab treatment shows a
remarkable increase in bone formation rate in early stage
(6 weeks) but such increase diminishes at the later stage
(26 weeks), which is characterized by a significant increase
in serum bone formation markers and decrease in bone
resorption markers [122]. However, as Wnt/b-catenin sig-
nalling pathway is elevated in osteosarcoma cells [123], the
relationship between long-term sclerostin inhibition and
the risk of bone cancer shall be investigated with regard to
the long-term safety of Scl-Ab administration.
The combined effects of Scl-Ab and other
osteoporotic drugs
An animal study has demonstrated that Scl-Ab treatment
has similar results in increase of bone formation, bone
mass, and bone strength with or without pretreatment of
alendronate, a widely used bisphosphonate, in OVX rats
[124]. Besides, cotreatment of Scl-Ab and alendronate have
Figure 3 Sclerostin monoclonal antibody (Scl-Ab) treatment
enhances bone formation in adult male rats. Scl-Ab treatment
enhances bone formation in both fractured bone and non-
8 P.K. Suen, L. Qinsimilar efficacies in bone formation, bone mass, and bone
strength to Scl-Ab alone or alendronate-pretreated OVX
rats [124]. These data suggest that Scl-Ab treatment does
not affect the previous alendronate treatment.
There is clinical interest in using monoclonal antibody
against DKK1 (DKK1-Ab) to treat multiple myeloma, as DKK1
produced by multiple myeloma cells is a key factor respon-
sible for bone loss in multiple myeloma [125]. In a transgenic
mouse model, it is clearly shown that the reduced DKK1
expression results in an increase in bone mass [63e65], thus
proposing the use of DKK1-Ab for treating osteoporosis. In
OVX animals, DKK1-Ab treatment improves bone formation
and bone mass [126]. As both Scl-Ab and DKK1-Ab are tar-
geted to upregulate the Wnt signalling pathway, the com-
bined effects of both antibodies may provide better
improvement in bone formation than single treatments.
The potential of drugedrug interaction of Scl-Ab and
other osteoporotic drugs have not been fully explored.
Future studies may also investigate the effectiveness of
combined treatment, especially in patients with severe
osteoporosis.fractured bone in adult male rats as early as 6 weeks after
the first injection. In nonfractured bone, Scl-Ab treatment is
more effective in enhancing bone formation especially in
trabecular bone region as shown by (A) micro-computed to-
mography (CT) 3D images and (B) micro-CT tomographs at
distal femur.(C) Fluorochrome labelling in the trabecular bone
at distal femur has also shown that Scl-Ab treatment increases
the rate of bone formation. In fractured bone, Scl-Ab treat-
ment promotes fracture healing through enhancing bone for-
mation in fracture callus, as evidenced by a larger callus
observed in (D) micro-CT 3D images and (E) radiographic im-
ages at femur midshaft.Scl-Ab treatment in male osteoporosis
Male osteoporosis is becoming a more important issue as
the population ages. Although research related to osteo-
porosis treatment mainly focuses on women, in fact, about
30% of hip fractures and 20% of vertebral fractures occur in
men [127,128] and the mortality associated with hip frac-
tures in elderly men is significantly higher than that in
women [129]. Scl-Ab treatment improves the bone forma-
tion, bone mass, and bone strength in aged male rats and
male cynomolgus monkeys [113,114]. Similarly, Scl-Ab has
been discovered to display anabolic effects in adult male
rats through increasing bone formation and bone mass,
especially in trabecular bone, as early as 6 weeks after the
first injection (Figure 3). These data support the use of
pharmacological drugs for osteoporosis treatment in men,
and currently several clinical trials have been undertaken
to investigate the potential use of current osteoporosis
drugs in men [130]. A recent study analysed the effects of
teriparatide for osteoporosis treatment in men. The
changes of BMD and bone turnover makers are directly
compared in men and women in the same study [131].
Differences in BMD of the lumbar spine and femoral neck,
and the serum P1NP biomarkers are found to be similar
between male and female groups [131]. Similar findings are
also observed in the clinical trials of Scl-Ab in healthy men
with low bone mass [23]. These findings suggest that the
osteoporosis drug treatments have similar bone anabolic
effects on both men and women. Further studies are
required to establish the efficacy in preventing bone frac-
tures and the safety of these treatments.Sclerostin monoclonal antibody for potential
healing enhancement of osteoporotic fracture
The effects of Scl-Ab treatment on fracture healing have
been investigated in various animal models. Scl-Ab treat-
ment increases bone mass and strength at the fracture sitein rats using either a closed femoral fracture model [114] or
a femoral osteotomy fracture model [119,132]. More bony
tissue and less cartilage tissue have been observed at the
fracture site in the rat femoral osteotomy fracture model
[119,132] and cynomolgus monkey bilateral fibular osteot-
omy model [114], indicating that Scl-Ab treatment is able
to enhance endochondral ossification during fracture
healing. Similarly, the bone mass and strength is increased
during fracture healing in SOST-KO mice, in both a femoral
closed fracture model [133] and a tibial closed fracture
model with external fixation [134]. In both models, the
endochondral ossification is hastened as evidenced by
increased cartilage removal [133,134]. These studies indi-
cate that downregulation of sclerostin expression enhanced
fracture healing through faster endochondral ossification.
As the downstream target of sclerostin, the Wnt/b-catenin
signalling pathway is well-known to be an important factor
to facilitate proper fracture healing [135]. Beta-catenin
signalling is activated in the fracture callus throughout
the entire period of fracture healing [136], and precise
regulation of b-catenin expression in the fracture site is
required for fracture healing [136]. Condition knock down
of the b-catenin gene expression in the fracture callus im-
pairs fracture healing [136]. The b-catenin level has also
been shown to elevate during the femoral bone defect
healing in SOST-KO mice [137], as well as open tibial frac-
ture healing in mice treated with DKK1-Ab treatment [138],
indicating that the inhibition of sclerostin or DKK1 promotes
Sclerostin in osteoporosis and treatment 9bone healing though activating the Wnt/b-catenin signal-
ling pathway. Although no investigations have been re-
ported that Scl-Ab treatment will activate the Wnt/b-
catenin signalling during fracture healing, results from
these two related studies [137,138] support that Scl-Ab
treatment shall also act through the same signalling
pathway to promote fracture healing.
Scl-Ab treatment also enhances bone repair in osteopo-
rotic condition. In a tibial drill-hole defect model in OVX
rat, Scl-Ab treatment accelerates the intramembranous
bone repair in both the trabecular bone and cortical bone of
the defect region [120]. This indicates that Scl-Ab treat-
ment also enhances bone formation and bone healing in
OVX conditions. In addition, based on our previous study in
rat femoral osteotomy healing, Scl-Ab treatment has
proven to enhance fracture healing through the hastened
endochondral ossification and improved angiogenesis [119]
(Figure 3). Angiogenesis is essential for bone healing, in
both normal and osteoporotic fracture healing [139,140].
Given that Scl-Ab improves fracture healing in a rat long-
bone closed fracture model [114], rat femoral osteotomy
[119] or cynomolgus monkey bilateral fibular osteotomy
model [114]. Scl-Ab is also expected to be able to improve
osteoporotic fracture healing. Clinical trials are essential to
support the potential routine applications of Scl-Ab for
fracture healing enhancement in osteoporotic patients,
apart from the known effects of Scl-Ab in the prevention of
secondary osteoporosis in this high-risk group.
Concluding remarks
The current understanding of Wnt signalling pathway in
regulating bone formation and remodelling provides
attractive strategies for developing new treatments for
osteoporosis and osteoporotic fracture repair. Sclerostin, as
an antagonist of the Wnt signalling pathway, is an effective
therapeutic target for osteoporosis treatment but its po-
tential for osteoporotic fracture repair still requires long-
term and perspective clinical trial studies for conformation.
As sclerostin is mainly expressed in bone cells, treatments
that inhibit sclerostin function should have minimal adverse
effects. Clinical trial studies have shown that the Scl-Ab
treatment has strong bone anabolic effects, and is effective
in improvement osteoporosis as compared with treatments
using other drugs. Future studies of Scl-Ab on its long-term
safety, drugedrug interaction, or synergistic effects and
male osteoporosis of Scl-Ab treatment may provide new
horizons for the osteoporosis as well as osteoporotic frac-
ture treatment.
Conflicts of interest
All the authors declare that they have no conflicts of
interest.
Funding/support
This study was supported by SMART Program, Lui Che Woo
Institute of Innovative Medicine, Faculty of Medicine, The
Chinese University of Hong Kong.References
[1] Burge R, Dawson-Hughes B, Solomon DH, Wong JB, King A,
Tosteson A. Incidence and economic burden of osteoporosis-
related fractures in the United States, 2005e2025. J Bone
Miner Res 2007;22:465e75.
[2] Johnell O, Kanis J. Epidemiology of osteoporotic fractures.
Osteoporos Int 2005;16(Suppl. 2):S3e7.
[3] Kanis JA, McCloskey EV, Johansson H, Oden A, Melton Jr L,
Khaltaev N. A reference standard for the description of
osteoporosis. Bone 2008;42:467e75.
[4] Assessment of fracture risk and its application to screening
for postmenopausal osteoporosis. Report of a WHO study
group. World Health Organ Tech Rep Ser 1994;843:1e129.
[5] Chau PH, Wong M, Lee A, Ling M, Woo J. Trends in hip frac-
ture incidence and mortality in Chinese population from
Hong Kong 2001e09. Age Ageing 2013;42:229e33.
[6] Kwok AW, Gong JS, Wang YX, Leung JC, Kwok T, Griffith JF,
et al. Prevalence and risk factors of radiographic vertebral
fractures in elderly Chinese men and women: results of Mr.
OS (Hong Kong) and Ms. OS (Hong Kong) studies. Osteoporos
Int 2013;24:877e85.
[7] Russell RG, Watts NB, Ebetino FH, Rogers MJ. Mechanisms of
action of bisphosphonates: similarities and differences and
their potential influence on clinical efficacy. Osteoporos Int
2008;19:733e59.
[8] Baron R, Ferrari S, Russell RG. Denosumab and bisphospho-
nates: different mechanisms of action and effects. Bone
2011;48:677e92.
[9] Suresh E, Pazianas M, Abrahamsen B. Safety issues with
bisphosphonate therapy for osteoporosis. Rheumatology
2014;53:19e31.
[10] Kharazmi M, Hallberg P, Warfvinge G, Michaelsson K. Risk of
atypical femoral fractures and osteonecrosis of the jaw
associated with alendronate use compared with other oral
bisphosphonates. Rheumatology 2014;53:1911e3.
[11] Rasmusson L, Abtahi J. Bisphosphonate associated osteo-
necrosis of the jaw: an update on pathophysiology, risk
factors, and treatment. Int J Dent 2014;2014:471035.
[12] McDonald MM, Dulai S, Godfrey C, Amanat N, Sztynda T,
Little DG. Bolus or weekly zoledronic acid administration
does not delay endochondral fracture repair but weekly
dosing enhances delays in hard callus remodeling. Bone 2008;
43:653e62.
[13] McDonald MM, Morse A, Mikulec K, Peacock L, Baldock PA,
Kostenuik PJ, et al. Matrix metalloproteinase-driven endo-
chondral fracture union proceeds independently of osteo-
clast activity. J Bone Miner Res 2013;28:1550e60.
[14] Fu LJ, Tang TT, Hao YQ, Dai KR. Long-term effects of
alendronate on fracture healing and bone remodeling of
femoral shaft in ovariectomized rats. Acta Pharmacol Sinica
2013;34:387e92.
[15] Savaridas T, Wallace RJ, Salter DM, Simpson AH. Do
bisphosphonates inhibit direct fracture healing?: a laboratory
investigation using an animal model. Bone Joint J 2013;95-B:
1263e8.
[16] Xue D, Li F, Chen G, Yan S, Pan Z. Do bisphosphonates affect
bone healing? A meta-analysis of randomized controlled tri-
als. J Orthop Surg Res 2014;9:45.
[17] Uihlein AV, Leder BZ. Anabolic therapies for osteoporosis.
Endocrinol Metab Clin North Am 2012;41:507e25.
[18] Yu B, Zhao X, Yang C, Crane J, Xian L, Lu W, et al. Para-
thyroid hormone induces differentiation of mesenchymal
stromal/stem cells by enhancing bone morphogenetic pro-
tein signaling. J Bone Miner Res 2012;27:2001e14.
[19] Jilka RL, Weinstein RS, Bellido T, Roberson P, Parfitt AM,
Manolagas SC. Increased bone formation by prevention of
10 P.K. Suen, L. Qinosteoblast apoptosis with parathyroid hormone. J Clin Invest
1999;104:439e46.
[20] Canalis E, Giustina A, Bilezikian JP. Mechanisms of anabolic
therapies for osteoporosis. N Engl J Med 2007;357:905e16.
[21] Vahle JL, Long GG, Sandusky G, Westmore M, Ma YL, Sato M.
Bone neoplasms in F344 rats given teriparatide [rhPTH(1-34)]
are dependent on duration of treatment and dose. Toxicol
Pathol 2004;32:426e38.
[22] Watanabe A, Yoneyama S, Nakajima M, Sato N, Takao-
Kawabata R, Isogai Y, et al. Osteosarcoma in Spra-
gueeDawley rats after long-term treatment with teripara-
tide (human parathyroid hormone (1-34)). J Toxicol Sci 2012;
37:617e29.
[23] Padhi D, Allison M, Kivitz AJ, Gutierrez MJ, Stouch B, Wang C,
et al. Multiple doses of sclerostin antibody romosozumab in
healthy men and postmenopausal women with low bone
mass: a randomized, double-blind, placebo-controlled study.
J Clin Pharmacol 2014;54:168e78.
[24] McClung MR, Grauer A, Boonen S, Bolognese MA, Brown JP,
Diez-Perez A, et al. Romosozumab in postmenopausal women
with low bone mineral density. N Engl J Med 2014;370:
412e20.
[25] Seeman E, Delmas PD. Bone qualitydthe material and
structural basis of bone strength and fragility. N Engl J Med
2006;354:2250e61.
[26] Katagiri T, Takahashi N. Regulatory mechanisms of osteoblast
and osteoclast differentiation. Oral Dis 2002;8:147e59.
[27] Feng X, McDonald JM. Disorders of bone remodeling. Annu
Rev Pathol 2011;6:121e45.
[28] Yasuda H, Shima N, Nakagawa N, Mochizuki SI, Yano K,
Fujise N, et al. Identity of osteoclastogenesis inhibitory
factor (OCIF) and osteoprotegerin (OPG): a mechanism by
which OPG/OCIF inhibits osteoclastogenesis in vitro. Endo-
crinology 1998;139:1329e37.
[29] Simonet WS, Lacey DL, Dunstan CR, Kelley M, Chang MS,
Luthy R, et al. Osteoprotegerin: a novel secreted protein
involved in the regulation of bone density. Cell 1997;89:
309e19.
[30] Martin TJ, Sims NA. Osteoclast-derived activity in the
coupling of bone formation to resorption. Trends Mol Med
2005;11:76e81.
[31] Das S, Crockett JC. Osteoporosisda current view of phar-
macological prevention and treatment. Drug Des Devel Ther
2013;7:435e48.
[32] Stagi S, Cavalli L, Iurato C, Seminara S, Brandi ML, de
Martino M. Bone metabolism in children and adolescents:
main characteristics of the determinants of peak bone mass.
Clin Cases Miner Bone Metab 2013;10:172e9.
[33] Qin L, Choy WY, Hung VWY, Au SK, Chan KH, Leung KS, et al.
Age-related vessel calcification at distal extremities is a risk
factor of osteoporosis. J Orthop Transl 2014;2:43e8.
[34] Clarke BL, Khosla S. Physiology of bone loss. Radiol Clin North
Am 2010;48:483e95.
[35] Balemans W, Ebeling M, Patel N, Van Hul E, Olson P,
Dioszegi M, et al. Increased bone density in sclerosteosis is
due to the deficiency of a novel secreted protein (SOST).
Hum Mol Genet 2001;10:537e43.
[36] Brunkow ME, Gardner JC, Van Ness J, Paeper BW,
Kovacevich BR, Proll S, et al. Bone dysplasia sclerosteosis
results from loss of the SOST gene product, a novel cystine
knot-containing protein. Am J Hum Genet 2001;68:577e89.
[37] Gardner JC, van Bezooijen RL, Mervis B, Hamdy NA,
Lowik CW, Hamersma H, et al. Bone mineral density in
sclerosteosis; affected individuals and gene carriers. J Clin
Endocrinol Metab 2005;90:6392e5.
[38] Staehling-Hampton K, Proll S, Paeper BW, Zhao L,
Charmley P, Brown A, et al. A 52-kb deletion in the SOST-
MEOX1 intergenic region on 17q12-q21 is associated withvan Buchem disease in the Dutch population. Am J Med
Genet 2002;110:144e52.
[39] Loots GG, Kneissel M, Keller H, Baptist M, Chang J,
Collette NM, et al. Genomic deletion of a long-range bone
enhancer misregulates sclerostin in Van Buchem disease.
Genome Res 2005;15:928e35.
[40] Winkler DG, Sutherland MK, Geoghegan JC, Yu C, Hayes T,
Skonier JE, et al. Osteocyte control of bone formation via
sclerostin, a novel BMP antagonist. EMBO J 2003;22:6267e76.
[41] Li X, Ominsky MS, Niu QT, Sun N, Daugherty B, D’Agostin D,
et al. Targeted deletion of the sclerostin gene in mice results
in increased bone formation and bone strength. J Bone Miner
Res 2008;23:860e9.
[42] Lin C, Jiang X, Dai Z, Guo X, Weng T, Wang J, et al. Sclerostin
mediates bone response to mechanical unloading through
antagonizing Wnt/beta-catenin signaling. J Bone Miner Res
2009;24:1651e61.
[43] Kramer I, Loots GG, Studer A, Keller H, Kneissel M. Para-
thyroid hormone (PTH)-induced bone gain is blunted in SOST
overexpressing and deficient mice. J Bone Miner Res 2010;25:
178e89.
[44] Li X, Zhang Y, Kang H, Liu W, Liu P, Zhang J, et al. Sclerostin
binds to LRP5/6 and antagonizes canonical Wnt signaling. J
Cell Biochem 2005;280:19883e7.
[45] Robling AG, Niziolek PJ, Baldridge LA, Condon KW, Allen MR,
Alam I, et al. Mechanical stimulation of bone in vivo reduces
osteocyte expression of Sost/sclerostin. J Cell Biochem 2008;
283:5866e75.
[46] Tu X, Rhee Y, Condon KW, Bivi N, Allen MR, Dwyer D, et al.
Sost downregulation and local Wnt signaling are required for
the osteogenic response to mechanical loading. Bone 2012;
50:209e17.
[47] Kim BJ, Bae SJ, Lee SY, Lee YS, Baek JE, Park SY, et al. TNF-
alpha mediates the stimulation of sclerostin expression in an
estrogen-deficient condition. Biochem Biophys Res Commun
2012;424:170e5.
[48] Fujita K, Roforth MM, Demaray S, McGregor U, Kirmani S,
McCready LK, et al. Effects of estrogen on bone mRNA levels
of sclerostin and other genes relevant to bone metabolism in
postmenopausal women. J Clin Endocrinol Metab 2014;99:
E81e8.
[49] Gaur T, Lengner CJ, Hovhannisyan H, Bhat RA, Bodine PV,
Komm BS, et al. Canonical WNT signaling promotes osteo-
genesis by directly stimulating Runx2 gene expression. J Cell
Biochem 2005;280:33132e40.
[50] Mendoza-Villanueva D, Zeef L, Shore P. Metastatic breast
cancer cells inhibit osteoblast differentiation through the
Runx2/CBFbeta-dependent expression of the Wnt antago-
nist, sclerostin. Breast Cancer Res 2011;13:R106.
[51] Atkins GJ, Rowe PS, Lim HP, Welldon KJ, Ormsby R,
Wijenayaka AR, et al. Sclerostin is a locally acting regulator
of late-osteoblast/preosteocyte differentiation and regu-
lates mineralization through a MEPE-ASARM-dependent
mechanism. J Bone Miner Res 2011;26:1425e36.
[52] Wijenayaka AR, Kogawa M, Lim HP, Bonewald LF, Findlay DM,
Atkins GJ. Sclerostin stimulates osteocyte support of osteo-
clast activity by a RANKL-dependent pathway. PLoS One
2011;6:e25900.
[53] Tu X, Delgado-Calle J, Condon KW, Maycas M, Zhang H,
Carlesso N, et al. Osteocytes mediate the anabolic actions of
canonical Wnt/beta-catenin signaling in bone. Proc Natl
Acad Sci U. S. A 2015;112:E478e86.
[54] Ota K, Quint P, Ruan M, Pederson L, Westendorf JJ, Khosla S,
et al. TGF-beta induces Wnt10b in osteoclasts from female
mice to enhance coupling to osteoblasts. Endocrinology
2013;154:3745e52.
[55] Pederson L, Ruan M, Westendorf JJ, Khosla S, Oursler MJ.
Regulation of bone formation by osteoclasts involves
Sclerostin in osteoporosis and treatment 11Wnt/BMP signaling and the chemokine sphingosine-1-
phosphate. Proc Natl Acad Sci U. S. A 2008;105:20764e9.
[56] Ota K, Quint P, Ruan M, Pederson L, Westendorf JJ, Khosla S,
et al. Sclerostin is expressed in osteoclasts from aged mice
and reduces osteoclast-mediated stimulation of mineraliza-
tion. J Cell Biochem 2013;114:1901e7.
[57] van Bezooijen RL, Roelen BA, Visser A, van der Wee-Pals L,
de Wilt E, Karperien M, et al. Sclerostin is an osteocyte-
expressed negative regulator of bone formation, but not a
classical BMP antagonist. J Exp Med 2004;199:805e14.
[58] Modder UI, Hoey KA, Amin S, McCready LK, Achenbach SJ,
Riggs BL, et al. Relation of age, gender, and bone mass to
circulating sclerostin levels in women and men. J Bone Miner
Res 2011;26:373e9.
[59] Garnero P, Sornay-Rendu E, Munoz F, Borel O, Chapurlat RD.
Association of serum sclerostin with bone mineral density,
bone turnover, steroid and parathyroid hormones, and frac-
ture risk in postmenopausal women: the OFELY study.
Osteoporos Int 2013;24:489e94.
[60] Krishnan V, Bryant HU, Macdougald OA. Regulation of bone
mass by Wnt signaling. J Clin Invest 2006;116:1202e9.
[61] Cong F, Schweizer L, Varmus H. Wnt signals across the plasma
membrane to activate the beta-catenin pathway by forming
oligomers containing its receptors, Frizzled and LRP. Devel-
opment 2004;131:5103e15.
[62] Agholme F, Aspenberg P. Wnt signaling and orthopedics, an
overview. Acta Orthop 2011;82:125e30.
[63] Li J, Sarosi I, Cattley RC, Pretorius J, Asuncion F, Grisanti M,
et al. Dkk1-mediated inhibition of Wnt signaling in bone re-
sults in osteopenia. Bone 2006;39:754e66.
[64] Morvan F, Boulukos K, Clement-Lacroix P, Roman Roman S,
Suc-Royer I, Vayssiere B, et al. Deletion of a single allele of
the Dkk1 gene leads to an increase in bone formation and
bone mass. J Bone Miner Res 2006;21:934e45.
[65] MacDonald BT, Joiner DM, Oyserman SM, Sharma P,
Goldstein SA, He X, et al. Bone mass is inversely proportional
to Dkk1 levels in mice. Bone 2007;41:331e9.
[66] Sakane H, Yamamoto H, Kikuchi A. LRP6 is internalized by
Dkk1 to suppress its phosphorylation in the lipid raft and is
recycled for reuse. J Cell Sci 2010;123:360e8.
[67] Mao B, Wu W, Davidson G, Marhold J, Li M, Mechler BM, et al.
Kremen proteins are Dickkopf receptors that regulate
Wnt/beta-catenin signalling. Nature 2002;417:664e7.
[68] van Dinther M, Zhang J, Weidauer SE, Boschert V, Muth EM,
Knappik A, et al. Anti-Sclerostin antibody inhibits internali-
zation of Sclerostin and Sclerostin-mediated antagonism of
Wnt/LRP6 signaling. PLoS One 2013;8:e62295.
[69] Grant BD, Donaldson JG. Pathways and mechanisms of
endocytic recycling. Nat Rev Mol Cell Biol 2009;10:597e608.
[70] Pangrazio A, Boudin E, Piters E, Damante G, Lo Iacono N,
D’Elia AV, et al. Identification of the first deletion in the LRP5
gene in a patient with autosomal dominant osteopetrosis
type I. Bone 2011;49:568e71.
[71] Balemans W, Piters E, Cleiren E, Ai M, Van Wesenbeeck L,
Warman ML, et al. The binding between sclerostin and LRP5
is altered by DKK1 and by high-bone mass LRP5 mutations.
Calcif Tissue Int 2008;82:445e53.
[72] Day TF, Guo X, Garrett-Beal L, Yang Y. Wnt/beta-catenin
signaling in mesenchymal progenitors controls osteoblast and
chondrocyte differentiation during vertebrate skeleto-
genesis. Dev Cell 2005;8:739e50.
[73] Weidauer SE, Schmieder P, Beerbaum M, Schmitz W,
Oschkinat H, Mueller TD. NMR structure of the Wnt modu-
lator protein Sclerostin. Biochem Biophys Res Commun 2009;
380:160e5.
[74] Boschert V, van Dinther M, Weidauer S, van Pee K, Muth EM,
Ten Dijke P, et al. Mutational analysis of sclerostin showsimportance of the flexible loop and the cystine-knot for Wnt-
signaling inhibition. PLoS One 2013;8:e81710.
[75] Veverka V, Henry AJ, Slocombe PM, Ventom A, Mulloy B,
Muskett FW, et al. Characterization of the structural features
and interactions of sclerostin: molecular insight into a key
regulator of Wnt-mediated bone formation. J Cell Biochem
2009;284:10890e900.
[76] Holdsworth G, Slocombe P, Doyle C, Sweeney B, Veverka V,
Le Riche K, et al. Characterization of the interaction of
sclerostin with the low density lipoprotein receptor-related
protein (LRP) family of Wnt co-receptors. J Cell Biochem
2012;287:26464e77.
[77] Dawson-Hughes B, Harris SS, Ceglia L, Palermo NJ. Effect of
supplemental vitamin D and calcium on serum sclerostin
levels. Eur J Endocrinol 2014;170:645e50.
[78] Sankaralingam A, Roplekar R, Turner C, Dalton RN,
Hampson G. Changes in Dickkopf-1 (DKK1) and sclerostin
following a loading dose of vitamin D 2 (300,000 IU). J
Osteoporos 2014;2014:682763.
[79] Cidem M, Karacan I, Arat NB, Zengi O, Ozkaya M, Guzel SP,
et al. Serum sclerostin is decreased following vitamin D
treatment in young vitamin D-deficient female adults.
Rheumatol Int 2015.
[80] Wijenayaka AR, Yang D, Prideaux M, Ito N, Kogawa M,
Anderson PH, et al. 1a,25-dihydroxyvitamin D stimulates
human SOST gene expression and sclerostin secretion. Mol
Cell Endocrinol 2015;413:157e67.
[81] Ryan ZC, Ketha H, McNulty MS, McGee-Lawrence M, Craig TA,
Grande JP, et al. Sclerostin alters serum vitamin D metabo-
lite and fibroblast growth factor 23 concentrations and the
urinary excretion of calcium. Proc Natl Acad Sci U. S. A 2013;
110:6199e204.
[82] Goltzman D. Inferences from genetically modified mouse
models on the skeletal actions of vitamin D. J Steroid Bio-
chem Mol Biol 2015;148:219e24.
[83] Bonewald LF, Johnson ML. Osteocytes, mechanosensing and
Wnt signaling. Bone 2008;42:606e15.
[84] Lara-Castillo N, Kim-Weroha NA, Kamel MA, Javaheri B,
Ellies DL, Krumlauf RE, et al. In vivo mechanical loading
rapidly activates beta-catenin signaling in osteocytes
through a prostaglandin mediated mechanism. Bone 2015;76:
58e66.
[85] Genetos DC, Yellowley CE, Loots GG. Prostaglandin E2 signals
through PTGER2 to regulate sclerostin expression. PLoS One
2011;6:e17772.
[86] Galea GL, Sunters A, Meakin LB, Zaman G, Sugiyama T,
Lanyon LE, et al. Sost down-regulation by mechanical strain
in human osteoblastic cells involves PGE2 signaling via EP4.
FEBS Lett 2011;585:2450e4.
[87] Zhou S. TGF-beta regulates beta-catenin signaling and
osteoblast differentiation in human mesenchymal stem cells.
J Cell Biochem 2011;112:1651e60.
[88] Loots GG, Keller H, Leupin O, Murugesh D, Collette NM,
Genetos DC. TGF-beta regulates sclerostin expression via the
ECR5 enhancer. Bone 2012;50:663e9.
[89] O’Brien CA, Plotkin LI, Galli C, Goellner JJ, Gortazar AR,
Allen MR, et al. Control of bone mass and remodeling by PTH
receptor signaling in osteocytes. PLoS One 2008;3:e2942.
[90] Keller H, Kneissel M. SOST is a target gene for PTH in bone.
Bone 2005;37:148e58.
[91] Mirza FS, Padhi ID, Raisz LG, Lorenzo JA. Serum sclerostin
levels negatively correlate with parathyroid hormone levels
and free estrogen index in postmenopausal women. J Clin
Endocrinol Metab 2010;95:1991e7.
[92] Ardawi MS, Al-Kadi HA, Rouzi AA, Qari MH. Determinants of
serum sclerostin in healthy pre- and postmenopausal women.
J Bone Miner Res 2011;26:2812e22.
12 P.K. Suen, L. Qin[93] Drake MT, Srinivasan B, Modder UI, Peterson JM,
McCready LK, Riggs BL, et al. Effects of parathyroid hormone
treatment on circulating sclerostin levels in postmenopausal
women. J Clin Endocrinol Metab 2010;95:5056e62.
[94] Piemonte S, Romagnoli E, Bratengeier C, Woloszczuk W,
Tancredi A, Pepe J, et al. Serum sclerostin levels decline in
post-menopausal women with osteoporosis following treat-
ment with intermittent parathyroid hormone. J Endocrinol
Invest 2012;35:866e8.
[95] Collette NM, Genetos DC, Economides AN, Xie L,
Shahnazari M, Yao W, et al. Targeted deletion of Sost distal
enhancer increases bone formation and bone mass. Proc Natl
Acad Sci U. S. A 2012;109:14092e7.
[96] Kramer I, Baertschi S, Halleux C, Keller H, Kneissel M. Mef2c
deletion in osteocytes results in increased bone mass. J Bone
Miner Res 2012;27:360e73.
[97] Leupin O, Kramer I, Collette NM, Loots GG, Natt F,
Kneissel M, et al. Control of the SOST bone enhancer by PTH
using MEF2 transcription factors. J Bone Miner Res 2007;22:
1957e67.
[98] Wein MN, Spatz J, Nishimori S, Doench J, Root D, Babij P,
et al. HDAC5 controls MEF2C-driven sclerostin expression in
osteocytes. J Bone Miner Res 2015;30:400e11.
[99] Baertschi S, Baur N, Lueders-Lefevre V, Voshol J, Keller H.
Class I and IIa histone deacetylases have opposite effects on
sclerostin gene regulation. J Biol Chem 2014;289:
24995e5009.
[100] Charopoulos I, Orme S, Giannoudis PV. The role and efficacy
of denosumab in the treatment of osteoporosis: an update.
Expert Opin Drug Saf 2011;10:205e17.
[101] Bone HG, Dempster DW, Eisman JA, Greenspan SL,
McClung MR, Nakamura T, et al. Odanacatib for the treat-
ment of postmenopausal osteoporosis: development history
and design and participant characteristics of LOFT, the Long-
Term Odanacatib Fracture Trial. Osteoporos Int 2015;26:
699e712.
[102] Dempster DW, Lambing CL, Kostenuik PJ, Grauer A. Role of
RANK ligand and denosumab, a targeted RANK ligand inhibi-
tor, in bone health and osteoporosis: a review of preclinical
and clinical data. Clin Ther 2012;34:521e36.
[103] Miller PD, Wagman RB, Peacock M, Lewiecki EM,
Bolognese MA, Weinstein RL, et al. Effect of denosumab on
bone mineral density and biochemical markers of bone
turnover: six-year results of a phase 2 clinical trial. J Clin
Endocrinol Metab 2011;96:394e402.
[104] Cummings SR, San Martin J, McClung MR, Siris ES, Eastell R,
Reid IR, et al. Denosumab for prevention of fractures in
postmenopausal women with osteoporosis. N Engl J Med
2009;361:756e65.
[105] Leung P, Pickarski M, Zhuo Y, Masarachia PJ, Duong LT. The
effects of the cathepsin K inhibitor odanacatib on osteo-
clastic bone resorption and vesicular trafficking. Bone 2011;
49:623e35.
[106] Pennypacker B, Shea M, Liu Q, Masarachia P, Saftig P,
Rodan S, et al. Bone density, strength, and formation in adult
cathepsin K (e/e) mice. Bone 2009;44:199e207.
[107] Pennypacker BL, Duong le T, Cusick TE, Masarachia PJ,
Gentile MA, Gauthier JY, et al. Cathepsin K inhibitors prevent
bone loss in estrogen-deficient rabbits. J Bone Miner Res
2011;26:252e62.
[108] Bone HG, McClung MR, Roux C, Recker RR, Eisman JA,
Verbruggen N, et al. Odanacatib, a cathepsin-K inhibitor for
osteoporosis: a two-year study in postmenopausal women
with low bone density. J Bone Miner Res 2010;25:937e47.
[109] Langdahl B, Binkley N, Bone H, Gilchrist N, Resch H, Rodri-
guez Portales J, et al. Odanacatib in the treatment of post-
menopausal women with low bone mineral density: five yearsof continued therapy in a phase 2 study. J Bone Miner Res
2012;27:2251e8.
[110] Ominsky MS, Vlasseros F, Jolette J, Smith SY, Stouch B,
Doellgast G, et al. Two doses of sclerostin antibody in cyn-
omolgus monkeys increases bone formation, bone mineral
density, and bone strength. J Bone Miner Res 2010;25:
948e59.
[111] Tian X, Jee WS, Li X, Paszty C, Ke HZ. Sclerostin antibody
increases bone mass by stimulating bone formation and
inhibiting bone resorption in a hindlimb-immobilization rat
model. Bone 2011;48:197e201.
[112] Li X, Ominsky MS, Warmington KS, Morony S, Gong J, Cao J,
et al. Sclerostin antibody treatment increases bone forma-
tion, bone mass, and bone strength in a rat model of post-
menopausal osteoporosis. J Bone Miner Res 2009;24:578e88.
[113] Li X, Warmington KS, Niu QT, Asuncion FJ, Barrero M,
Grisanti M, et al. Inhibition of sclerostin by monoclonal
antibody increases bone formation, bone mass, and bone
strength in aged male rats. J Bone Miner Res 2010;25:
2647e56.
[114] Ominsky MS, Li C, Li X, Tan HL, Lee E, Barrero M, et al. In-
hibition of sclerostin by monoclonal antibody enhances bone
healing and improves bone density and strength of non-
fractured bones. J Bone Miner Res 2011;26:1012e21.
[115] Tian X, Setterberg RB, Li X, Paszty C, Ke HZ, Jee WS.
Treatment with a sclerostin antibody increases cancellous
bone formation and bone mass regardless of marrow
composition in adult female rats. Bone 2010;47:529e33.
[116] Rossini M, Gatti D, Adami S. Involvement of WNT/beta-
catenin signaling in the treatment of osteoporosis. Calcif
Tissue Int 2013;93:121e32.
[117] Spatz JM, Ellman R, Cloutier AM, Louis L, van Vliet M,
Suva LJ, et al. Sclerostin antibody inhibits skeletal deterio-
ration due to reduced mechanical loading. J Bone Miner Res
2013;28:865e74.
[118] Agholme F, Li X, Isaksson H, Ke HZ, Aspenberg P. Sclerostin
antibody treatment enhances metaphyseal bone healing in
rats. J Bone Miner Res 2010;25:2412e8.
[119] Suen PK, He YX, Chow DH, Huang L, Li C, Ke HZ, et al.
Sclerostin monoclonal antibody enhanced bone fracture
healing in an open osteotomy model in rats. J Orthop Res
2014;32:997e1005.
[120] McDonald MM, Morse A, Mikulec K, Peacock L, Yu N,
Baldock PA, et al. Inhibition of sclerostin by systemic treat-
ment with sclerostin antibody enhances healing of proximal
tibial defects in ovariectomized rats. J Orthop Res 2012;30:
1541e8.
[121] Padhi D, Jang G, Stouch B, Fang L, Posvar E. Single-dose,
placebo-controlled, randomized study of AMG 785, a scle-
rostin monoclonal antibody. J Bone Miner Res 2011;26:
19e26.
[122] Stolina M, Dwyer D, Niu QT, Villasenor KS, Kurimoto P,
Grisanti M, et al. Temporal changes in systemic and local
expression of bone turnover markers during six months of
sclerostin antibody administration to ovariectomized rats.
Bone 2014;67:305e13.
[123] Cai Y, Cai T, Chen Y. Wnt pathway in osteosarcoma, from
oncogenic to therapeutic. J Cell Biochem 2014;115:625e31.
[124] Li X, Ominsky MS, Warmington KS, Niu QT, Asuncion FJ,
Barrero M, et al. Increased bone formation and bone mass
induced by sclerostin antibody is not affected by pretreat-
ment or cotreatment with alendronate in osteopenic,
ovariectomized rats. Endocrinology 2011;152:3312e22.
[125] Qiang YW, Barlogie B, Rudikoff S, Shaughnessy Jr JD. Dkk1-
induced inhibition of Wnt signaling in osteoblast differenti-
ation is an underlying mechanism of bone loss in multiple
myeloma. Bone 2008;42:669e80.
Sclerostin in osteoporosis and treatment 13[126] Glantschnig H, Scott K, Hampton R, Wei N, McCracken P,
Nantermet P, et al. A rate-limiting role for Dickkopf-1 in bone
formation and the remediation of bone loss in mouse and
primate models of postmenopausal osteoporosis by an
experimental therapeutic antibody. J Pharmacol Exp Ther
2011;338:568e78.
[127] Eastell R, Boyle IT, Compston J, Cooper C, Fogelman I,
Francis RM, et al. Management of male osteoporosis: report
of the UK Consensus Group. QJM 1998;91:71e92.
[128] Legrand E, Chappard D, Pascaretti C, Duquenne M,
Rondeau C, Simon Y, et al. Bone mineral density and
vertebral fractures in men. Osteoporos Int 1999;10:
265e70.
[129] Johnell O, Kanis JA. An estimate of the worldwide preva-
lence and disability associated with osteoporotic fractures.
Osteoporos Int 2006;17:1726e33.
[130] Giusti A, Bianchi G. Treatment of primary osteoporosis in
men. Clin Interv Aging 2015;10:105e15.
[131] Niimi R, Kono T, Nishihara A, Hasegawa M, Matsumine A,
Sudo A. Analysis of daily teriparatide treatment for osteo-
porosis in men. Osteoporos Int 2015.
[132] Feng G, Chang-Qing Z, Yi-Min C, Xiao-Lin L. Systemic
administration of sclerostin monoclonal antibody accelerates
fracture healing in the femoral osteotomy model of young
rats. Int Immunopharmacol 2015;24:7e13.
[133] Li C, Ominsky MS, Tan HL, Barrero M, Niu QT, Asuncion FJ,
et al. Increased callus mass and enhanced strength duringfracture healing in mice lacking the sclerostin gene. Bone
2011;49:1178e85.
[134] Morse A, Yu NY, Peacock L, Mikulec K, Kramer I, Kneissel M,
et al. Endochondral fracture healing with external fixation in
the Sost knockout mouse results in earlier fibrocartilage
callus removal and increased bone volume fraction and
strength. Bone 2015;71:155e63.
[135] Silkstone D, Hong H, Alman BA. Beta-catenin in the race to
fracture repair: in it to Wnt. Nat Clin Pract Rheumatol 2008;
4:413e9.
[136] Chen Y, Whetstone HC, Lin AC, Nadesan P, Wei Q, Poon R,
et al. Beta-catenin signaling plays a disparate role in
different phases of fracture repair: implications for therapy
to improve bone healing. PLoS Med 2007;4:e249.
[137] McGee-Lawrence ME, Ryan ZC, Carpio LR, Kakar S,
Westendorf JJ, Kumar R. Sclerostin deficient mice rapidly
heal bone defects by activating beta-catenin and increasing
intramembranous ossification. Biochem Biophys Res Commun
2013;441:886e90.
[138] Jin H, Wang B, Li J, Xie W, Mao Q, Li S, et al. Anti-DKK1
antibody promotes bone fracture healing through activation
of beta-catenin signaling. Bone 2015;71:63e75.
[139] Hankenson KD, Dishowitz M, Gray C, Schenker M. Angiogen-
esis in bone regeneration. Injury 2011;42:556e61.
[140] Gruber R, Koch H, Doll BA, Tegtmeier F, Einhorn TA,
Hollinger JO. Fracture healing in the elderly patient. Exp
Gerontol 2006;41:1080e93.
